Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

 Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

Shots:

  • The P-III program consists of two trials (ISABELA 1 & 2) assessing ziritaxesta (200/ 600mg, qd) + SOC vs PBO + SOC in ~1500 patients with IPF. The 1EPs of the study decline in forced vital capacity until 52wks.
  • The termination of the study is based IDMC’s recommendation following a regular review of unblinded data, which concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies
  • Ziritaxestat is an investigational autotaxin inhibitor. Additionally, all clinical trials with ziritaxestat includes the long-term extension of P-IIa NOVESA trial in systemic sclerosis will be discontinued

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Made in

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post